Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
29.42
-0.24 (-0.81%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pfizer
< Previous
1
2
3
4
5
6
7
8
9
...
34
35
Next >
Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
July 30, 2024
The healthcare sector, represented by the XLV ETF, has seen a resurgence, breaking out of a multi-year consolidation phase and surging almost 3% in July.
Via
MarketBeat
Topics
ETFs
Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance
July 30, 2024
From
Pfizer Inc.
Via
Business Wire
European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B
July 25, 2024
From
Pfizer Inc.
Via
Business Wire
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
July 25, 2024
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate
July 24, 2024
From
Pfizer Inc.
Via
Business Wire
Positive News is Driving This Cancer Drug Maker’s Stock Higher
July 15, 2024
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather
Via
MarketBeat
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
July 25, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA
July 11, 2024
Via
AB Newswire
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
July 11, 2024
From
Pfizer Inc.
Via
Business Wire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Names Four New Members to Executive Team
July 09, 2024
Via
Investor Brand Network
Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development
July 09, 2024
From
Pfizer Inc.
Via
Business Wire
FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment
July 09, 2024
Via
AB Newswire
Exposures
COVID-19
Product Safety
MarketBeat Week in Review – 7/1 - 7/5
July 06, 2024
The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
3 Stock Giants Analysts Are Bullish On Despite Struggles
July 05, 2024
Despite recent struggles, PYPL, BABA, and PFE present attractive opportunities with favorable P/Es, high dividend yields, and analyst-predicted upsides.
Via
MarketBeat
AbbVie Stock: A Perfect Dip for Investors to Buy
July 03, 2024
ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors
Via
MarketBeat
Topics
ETFs
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
July 03, 2024
Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases
Via
MarketBeat
Exposures
Product Safety
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
July 02, 2024
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout.
Via
MarketBeat
Topics
ETFs
Exposures
COVID-19
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
July 02, 2024
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy
Via
MarketBeat
Cyrus Taraporevala Elected to Pfizer’s Board of Directors
July 01, 2024
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
June 27, 2024
From
Pfizer Inc.
Via
Business Wire
Pfizer Declares Third-Quarter 2024 Dividend
June 26, 2024
From
Pfizer Inc.
Via
Business Wire
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
June 18, 2024
From
Pfizer Inc.
Via
Business Wire
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
June 17, 2024
Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA
Via
MarketBeat
Exposures
COVID-19
Precision Medicine M&A is Transforming the Future of the Biotech Industry
June 17, 2024
Via
AB Newswire
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
June 14, 2024
From
Pfizer Inc.
Via
Business Wire
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy
June 12, 2024
From
Pfizer Inc.
Via
Business Wire
Meme Stocks Surge Led by ‘Roaring Kitty’ and Social Media Buzz on Reddit (NYSE: RDDT), GME, DYAI, AMC, PRSO, NVAX
June 06, 2024
Via
AB Newswire
Novavax Stock’s Recent Surge and Future Potential
June 06, 2024
Novavax's future hinges on its ability to translate recent stock market momentum into sustained financial performance.
Via
MarketBeat
Topics
Economy
Exposures
COVID-19
Product Safety
Supply Chain
Dyadic International Inc. (NASDAQ: DYAI) Hits New 52-Week High Amidst Golden Cross, Bullish Swing Patterns and Bird Flu Concerns
June 06, 2024
Via
AB Newswire
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
June 05, 2024
Initial triplet combination of RLY-2608 + atirmociclib + fulvestrant to be evaluated in patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
34
35
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.